文献速递乳腺癌

CDK4/6抑制剂治疗激素受体阳性HER2阴性晚期或转移性乳腺癌:美国FDA汇总分析

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
PubMed 文献 · Lancet Oncol · 2019-12-16

该汇总分析纳入7项提交FDA的III期随机试验的4200例患者个体数据,评估CDK4/6抑制剂联合内分泌治疗对比安慰剂联合内分泌治疗。

要点

  • 所有预设临床病理亚组均显示PFS获益,HR与总体人群相似。

核心结论

  • 在激素受体阳性HER2阴性晚期或转移性乳腺癌中,CDK4/6抑制剂联合内分泌治疗较安慰剂联合内分泌治疗显著改善无进展生存期,且在所有预设临床病理亚组中均观察到获益。

研究设计与样本

  • 汇总分析纳入2019年1月1日前提交美国FDA支持上市申请的所有CDK4/6抑制剂联合内分泌治疗的III期随机乳腺癌试验的个体患者数据。
  • 共纳入7项研究,4200例随机分配并接受至少一剂CDK4/6抑制剂或安慰剂联合内分泌治疗(芳香化酶抑制剂或氟维司群)的患者。
  • 主要终点为研究者评估的无进展生存期,采用Kaplan-Meier法估计中位PFS,Cox回归模型估计HR及95%CI。

主要发现

  • 所有预设临床病理亚组(包括孕激素受体阴性、无病间期≤12个月、新发转移、小叶组织学、仅骨转移、内脏转移及年龄≤40岁)的PFS结果均支持CDK4/6抑制剂组,HR与总体意向人群相似。

临床怎么用

  • 对于激素受体阳性HER2阴性晚期或转移性乳腺癌,CDK4/6抑制剂联合内分泌治疗(芳香化酶抑制剂或氟维司群)可作为一线或二线及以上治疗选择,各临床病理亚组均可考虑获益。

局限性

  • 研究未纳入未治疗、接受他莫昔芬或既往在转移阶段接受过化疗(非一线)的患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indicated with endocrine therapy as first-line or second-line treatment for hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. We aimed to investigate the benefit of adding CDKIs to endocrine therapy in patients whose tumours might have differing degrees of endocrine sensitivity. METHODS: We pooled individual patient data from all phase 3 randomised breast cancer trials of CDKIs plus endocrine therapy submitted to the US Food and Drug Administration before Jan 1, 2019, in support of marketing applications. Our pooled analysis included all randomly assigned patients in these trials who received at least one dose of CDKI or placebo with endocrine therapy (an aromatase inhibitor [letrozole or anastrazole] or fulvestrant). We did prespecified subgroup analyses in patients with progesterone receptor-negative disease; patients with a disease-free interval of 12 months or less; patients with de-novo metastases, lobular histology, and bone-only disease; patients with visceral metastases; and patients aged up to 40 years. Patients who were not treated, who received tamoxifen as endocrine therapy, or who were treated with an aromatase inhibitor but who had received previous chemotherapy in the metastatic setting (not first-line) were excluded from our pooled analyses. All studies had a primary endpoint of investigator-assessed progression-free survival, defined as time from date of randomisation to the initial date of documented cancer progression or death, whichever occurred first. Median progression-free survival was estimated with Kaplan-Meier methods. Hazard ratios (HR) with 95% CIs for progression-free survival were estimated by means of Cox regression models. FINDINGS: The seven studies meeting this study's inclusion criteria were done between Feb 22, 2013, and Nov 3, 2017, with a median duration of follow-up of 19·7 months (IQR 15·9-25·9). 4200 patients were included in the pooled analysis, of whom 1320 received an aromatase inhibitor plus a CDKI, 932 received placebo plus an aromatase inhibitor, 1296 received fulvestrant plus a CDKI, and 652 received fulvestrant plus placebo. Across all seven pooled trials, the difference in estimated median progression-free survival was 8·8 months in favour of CDKI plus endocrine therapy over placebo plus endocrine therapy (range across the trials 6·8-13·3 months; HR 0·59, 95% CI 0·54-0·64). Progression-free survival results favoured the CDKI group in all prespecified clinicopathological subgroups analysed, with similar HRs to that for the broader intended-use population. In first-line aromatase inhibitor-treated patients (n=2252), the median progression-free survival in the CDKI plus aromatase inhibitor group was 28·0 months (95% CI 25·3-29·1) versus 14·9 months (14·0-16·7) in the placebo plus aromatase inhibitor group (difference 13·1 months; range across the trials 13·0-13·3 months; HR 0·55, 95% CI 0·49-0·62). In first-line fulvestrant-treated patients (n=396), the median progression-free survival was 18·6 months (95% CI 14·8-23·5) in the placebo plus fulvestrant group and not estimable (22·4 to not estimable) in the CDKI plus fulvestrant group (difference not estimable; HR 0·58, 95% CI 0·42-0·80). In the patients treated with fulvestrant in the second-line setting and beyond (n=1552), the difference in estimated median progression-free survival between the CDKI plus fulvestrant group and the placebo plus fulvestrant group was 6·9 months in favour of the CDKI group (range across the trials 5·5-7·3 months; HR 0·56, 95% CI 0·49-0·64). INTERPRETATION: Since the addition of CDKI to endocrine therapy seemed to benefit all clinicopathological subgroups of interest in this pooled analysis, further research is needed to identify patient subgroups for whom endocrine therapy alone might be appropriate for first-line or second-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2019. PMID: 31859246. doi:10.1016/S1470-2045(19)30804-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。